Xaliproden

From WikiMD.org
Jump to navigation Jump to search

Xaliproden

Xaliproden (pronounced: zah-lih-PRO-den) is a neuroprotective agent that was under development for the treatment of Amyotrophic lateral sclerosis (ALS) and chemotherapy-induced peripheral neuropathy (CIPN).

Etymology

The term "Xaliproden" is a coined name, with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.

Usage

Xaliproden was investigated for its potential to slow the progression of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. It was also studied for its potential to prevent or reduce CIPN, a common side effect of certain chemotherapy drugs.

Mechanism of Action

Xaliproden is believed to work by protecting nerve cells from damage. It is a serotonin 1A receptor agonist, which means it binds to and activates these receptors in the brain. This activation is thought to have neuroprotective effects.

Clinical Trials

Several clinical trials were conducted to evaluate the safety and efficacy of Xaliproden in patients with ALS and CIPN. However, the drug did not show sufficient benefit in these trials and development was discontinued.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski